Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein A1 pseudogene 74 (HNRNPA1P74) is classified as a pseudogene, specifically a non-coding genomic region originating from the parent gene *HNRNPA1*. Pseudogenes are typically non-functional remnants of genes that have lost their ability to encode functional proteins due to mutations or truncations[1][3][4]. While some pseudogenes can have regulatory roles at the RNA level (such as acting as competitive endogenous RNAs or producing regulatory RNAs in some contexts[5]), there is no evidence that HNRNPA1P74 has such a function. HNRNPA1P74 does not encode a protein, is not a known drug target, and has no recognized physiological or disease association distinct from its parent gene, **HNRNPA1**, which itself is an RNA-binding protein involved in splicing and found to be important in several cancers[2]. Therefore, HNRNPA1P74 should not be considered a bona fide molecular target for therapeutic, diagnostic, or functional studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1 pseudogene 74 (HNRNPA1P74).